Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarek Assi

Showing results (11-20 of 120) with videos related to

Pageof 12
Sort By:
Immunotherapy|September 9, 2025
Cracking the code: the emerging role of immune checkpoint inhibitors in PEComasTarek Assi, Axel Le Cesne
British Journal of Cancer|February 12, 2020
Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?Elie Rassy, Tarek Assi, Nicholas Pavlidis
Anti-Cancer Drugs|August 18, 2021
Long-term extracranial metastatic relapse of an intraventricular solitary fibrous tumor: a case reportTarek Assi, Elie Samaha, Hussein Nassereddine
Future Oncology (London, England)|November 16, 2019
Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?Elie Rassy, Tarek Assi, Joseph Kattan
Immunotherapy|April 16, 2020
Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?Joseph Kattan, Clarisse Kattan, Tarek Assi
Bulletin Du Cancer|May 7, 2018
[Adherence to the Clinical Practice Guidelines in the management of Soft Tissue Sarcomas in Lebanon: Lessons from French Sarcoma Group's experience]Tarek Assi, Elie El Rassy, Joseph Kattan
Future Oncology (London, England)|November 26, 2016
Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?Elie El Rassy, Tarek Assi, Joseph Kattan
Immunotherapy|March 31, 2025
Exploring the role of immune checkpoint inhibitors in solitary fibrous tumorsTarek Assi, Tania Moussa, Axel Le Cesne
Immunotherapy|December 9, 2020
Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?Tarek Assi, Axel Le Cesne, Olivier Mir
Anti-Cancer Drugs|September 7, 2019
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case reportJoseph Kattan, Clarisse Kattan, Fadi Farhat, et al.
Pageof 12

Showing results (11-20 of 120) with videos related to

Sort By:
Pageof 12
Immunotherapy|September 9, 2025
Cracking the code: the emerging role of immune checkpoint inhibitors in PEComasTarek Assi, Axel Le Cesne
British Journal of Cancer|February 12, 2020
Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?Elie Rassy, Tarek Assi, Nicholas Pavlidis
Anti-Cancer Drugs|August 18, 2021
Long-term extracranial metastatic relapse of an intraventricular solitary fibrous tumor: a case reportTarek Assi, Elie Samaha, Hussein Nassereddine
Future Oncology (London, England)|November 16, 2019
Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?Elie Rassy, Tarek Assi, Joseph Kattan
Immunotherapy|April 16, 2020
Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?Joseph Kattan, Clarisse Kattan, Tarek Assi
Bulletin Du Cancer|May 7, 2018
[Adherence to the Clinical Practice Guidelines in the management of Soft Tissue Sarcomas in Lebanon: Lessons from French Sarcoma Group's experience]Tarek Assi, Elie El Rassy, Joseph Kattan
Future Oncology (London, England)|November 26, 2016
Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?Elie El Rassy, Tarek Assi, Joseph Kattan
Immunotherapy|March 31, 2025
Exploring the role of immune checkpoint inhibitors in solitary fibrous tumorsTarek Assi, Tania Moussa, Axel Le Cesne
Immunotherapy|December 9, 2020
Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?Tarek Assi, Axel Le Cesne, Olivier Mir
Anti-Cancer Drugs|September 7, 2019
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case reportJoseph Kattan, Clarisse Kattan, Fadi Farhat, et al.
Pageof 12